Mistletoe therapy in oncology (2008)

Peer-Reviewed Study · Horneber MA, Bueschel G, Huber R, Linde K, Rostock M (Cochrane Database Syst Rev 2008;(2):CD003297) · April 16, 2008

Horneber MA et al., 2008-04-16: Cochrane review of mistletoe extracts in oncology. Evidence for survival or tumour benefit is weak; some trials suggested quality-of-life benefit during chemotherapy for breast cancer, which the authors say needs replication.

The evidence from RCTs to support the view that the application of mistletoe extracts has impact on survival or leads to an improved ability to fight cancer or to withstand anticancer treatments is weak.

Abstract (AUTHORS' CONCLUSIONS)

Horneber MA et al., 2008-04-16: Cochrane review of mistletoe extracts in oncology. Evidence for survival or tumour benefit is weak; some trials suggested quality-of-life benefit during chemotherapy for breast cancer, which the authors say needs replication. Funder: external – Deutsche Krebshilfe 'Arbeitsgruppe Biologische Krebstherapie' and ViFAB (Denmark). Conflicts: RH and MR received research funding for mistletoe research from mistletoe manufacturers and honoraria for lectures from manufacturers – a direct industry tie disclosed in a review about that industry's product. Product: mistletoe (Viscum album) extracts, chiefly Iscador/Abnoba-viscum; makers not named in the review. Comparator: placebo or no mistletoe alongside conventional treatment. Marked 'Stable' – no update expected. PMC7144832. Study type: review.